Niraparib/abiraterone acetate

Niraparib/Abiraterone Acetate is a combination of two drugs, Niraparib and Abiraterone Acetate, used in the treatment of certain types of cancer.

Niraparib

Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor used primarily in the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It works by inhibiting the enzyme PARP, which is involved in DNA repair. By inhibiting this enzyme, DNA damage in cancer cells accumulates, leading to cell death.

Abiraterone Acetate

Abiraterone Acetate is a CYP17 inhibitor used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting the production of androgens (male hormones) which are known to fuel the growth of prostate cancer.

Combination Therapy

The combination of Niraparib and Abiraterone Acetate is currently being studied in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The rationale behind this combination is to exploit the synergistic effects of a PARP inhibitor and a CYP17 inhibitor in treating prostate cancer.

Side Effects

Like all medications, Niraparib and Abiraterone Acetate can cause side effects. Common side effects of Niraparib include nausea, fatigue, constipation, and thrombocytopenia. Common side effects of Abiraterone Acetate include fatigue, joint pain, hypertension, and hypokalemia.

See Also

• PARP inhibitor
• CYP17 inhibitor
• Ovarian cancer
• Prostate cancer